Literature DB >> 16778187

p53 down-regulates phosphatase and tensin homologue deleted on chromosome 10 protein stability partially through caspase-mediated degradation in cells with proteasome dysfunction.

Yufang Tang1, Charis Eng.   

Abstract

There has been intense investigation regarding the interaction between the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and p53 tumor suppressors. p53 has been shown to up-regulate PTEN expression as a transcriptional activator. However, clinical observations by immunohistochemistry studies indicate that significant increases in p53 protein levels coexist with reduced or absent expression of PTEN protein in a variety of neoplasias. In this study, we propose a mechanism that begins to explain how p53 can both up-regulate and down-regulate PTEN. We have found that PTEN protein is down-regulated under proteasome dysfunction induced by proteasome inhibitor MG132 in both human lymphoblast cells and MCF7 cells. The reduction of PTEN is coincident with elevated p53 protein levels and the association between PTEN and p53 but independent of its phosphatase activities. Quantitative reverse transcription-PCR indicates that proteasome inhibition does not reduce PTEN message levels but affects PTEN protein stability. The p53 inhibitor, pifithrin-alpha, is able to attenuate the effect of proteasome inhibition. Using ectopic expression studies in p53-null mouse embryonic fibroblasts and p53/PTEN-null PC3 cells, we show that PTEN is more stable in p53-null cells compared with p53-expressing cells. Inhibition of caspases, the downstream targets of p53, particularly caspase-3, can partially restore the stability of PTEN. This study provides the first evidence that p53 is able to down-regulate PTEN protein stability in stressed cells. Our study sheds some light on the mechanisms that regulate PTEN protein stability, which is important to fully elucidate to comprehend the broad neoplastic manifestations of Cowden syndrome/Bannayan-Riley-Ruvalcaba and sporadic cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778187     DOI: 10.1158/0008-5472.CAN-06-0772

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Association of PTEN gene polymorphisms with liver cancer risk.

Authors:  Hong-Guang Li; Fang-Feng Liu; Hua-Qiang Zhu; Xu Zhou; Jun Lu; Hong Chang; Jin-Hua Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  PTEN in liver diseases and cancer.

Authors:  Marion Peyrou; Lucie Bourgoin; Michelangelo Foti
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

3.  The Role of PTEN in β-Cell Growth.

Authors:  Ni Zeng; Jennifer-Ann Bayan; Lina He; Bangyan Stiles
Journal:  Open Endocrinol J       Date:  2010

4.  Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes.

Authors:  Ying Ni; Kevin M Zbuk; Tammy Sadler; Attila Patocs; Glenn Lobo; Emily Edelman; Petra Platzer; Mohammed S Orloff; Kristin A Waite; Charis Eng
Journal:  Am J Hum Genet       Date:  2008-08       Impact factor: 11.025

5.  Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest.

Authors:  Emily A Nizialek; Charissa Peterson; Jessica L Mester; Erinn Downes-Kelly; Charis Eng
Journal:  Hum Mol Genet       Date:  2013-02-27       Impact factor: 6.150

6.  Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation.

Authors:  Rosemary E Teresi; Kevin M Zbuk; Marcus G Pezzolesi; Kristin A Waite; Charis Eng
Journal:  Am J Hum Genet       Date:  2007-08-15       Impact factor: 11.025

7.  PTEN gene: a model for genetic diseases in dermatology.

Authors:  Corrado Romano; Carmelo Schepis
Journal:  ScientificWorldJournal       Date:  2012-04-30

Review 8.  Orofacial Manifestations Assisting the Diagnosis of Cowden Syndrome in a Middle-Aged Patient: Case Report and Literature Overview.

Authors:  Sebastião Silvério Sousa-Neto; José Alcides Almeida de Arruda; Allisson Filipe Lopes Martins; Lucas Guimarães Abreu; Ricardo Alves Mesquita; Elismauro Francisco Mendonça
Journal:  Head Neck Pathol       Date:  2021-06-09

9.  Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance.

Authors:  Mohan Singh; Parvesh Chaudhry; Francois Fabi; Eric Asselin
Journal:  BMC Cancer       Date:  2013-05-10       Impact factor: 4.430

10.  Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress.

Authors:  Carlos Farkas; Carla P Martins; David Escobar; Matias I Hepp; Ariel F Castro; Gerard Evan; José L Gutiérrez; Robert Warren; David B Donner; Roxana Pincheira
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.